Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

42 results about "Muscle weakness" patented technology

Reduction in the power exerted by muscles resulting in an inability to perform a given task on first attempt.

HERV-k (HML-2) ENV analog fusion proteins for antigen specific immunotherapy and methods of use

ActiveUS20260035414A1Nervous disorderAntibody mimetics/scaffoldsDiseaseMuscular weakness
The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.
Owner:TWILIGHT BIOSCIENCE INC

Activin receptor type IIB variants and uses thereof

PendingJP2026501203AFungiBacteriaTruncal muscle weaknessCardiometabolic disease
There remains a need for effective therapeutic agents for the treatment of TGFβ superfamily-associated disorders. [Solution] Polypeptides comprising an activin receptor type IIB (ActRIIB) ectodomain (ECD) variant are provided. In some embodiments, the polypeptides of the present disclosure comprise an ActRIIB-ECD variant fused to an Fc domain portion. The present disclosure also provides pharmaceutical compositions and methods using the polypeptides to treat diseases and conditions associated with TGF-β superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (e.g., anemia).
Owner:35PHARMA INC

Application of epimedin A as unique active ingredient in preparation of medicine for preventing and / or improving sarcopenia

PendingCN121891388AOrganic active ingredientsMuscular disorderLiver and kidneyTruncal muscle weakness
The invention relates to application of traditional Chinese medicine herba epimedii, especially an aqueous extract of herba epimedii and epimedin A in prevention and / or improvement of sarcopenia. Compared with a blank control group and a negative control group, the body lengths of the herba epimedii aqueous extract with the concentration of 1 mg / mL, the total flavonoids with the concentration of 0.026 mg / mL, the epimedium A with the concentration of 50 [mu] M, the epimedium B with the concentration of 200 [mu] M, the epimedium C with the concentration of 100 [mu] M, the icariin with the concentration of 200 [mu] M and the icaritin with the concentration of 100 [mu] M are increased by 21.40%, 23.09%, 26.69%, 24.91%, 29.22%, 33.15% and 28.35% respectively. The icariin administration concentration is improved, and the growth promoting effect concentration dependence is obviously enhanced. The body length of the caenorhabditis elegans is increased by 24.19% and even exceeds that of a positive control group. Epimedin A of 50 mu M can effectively increase the body length of caenorhabditis elegans, and other Epimedin A needs higher concentration; 50 [mu] M has the best effect of protecting and relieving the muscular structure. The invention provides a thought for developing medicines for improving dyskinesia and muscle volume reduction, prolonging life, improving muscle fiber atrophy, treating muscle strength decline, tonifying liver and kidney and strengthening muscles and bones, and the medicine is high in safety.
Owner:GANSU UNIV OF CHINESE MEDICINE

System

An object of a system according to an embodiment is to convey warmth of handwritten characters even to a user with weakened muscle strength.SOLUTION: A system according to an embodiment includes a line-of-sight tracking unit, a character generation unit, a writing pressure addition unit, and a fluctuation addition unit. The eye tracking unit tracks the user's eye using the eye input device and identifies the selected character. The character generation unit analyzes the character information specified by the line-of-sight tracking unit, and generates a character based on the style of the past handwritten character of the user. The writing pressure applying section applies a writing pressure to the character generated by the character generating section. The fluctuation addition section adds a fluctuation to the character generated by the character generation section.SELECTED DRAWING: Figure 1
Owner:SOFTBANK GROUP CORP

Use of s100a8 / a9 and complement 3 inhibitors in the preparation of a medicament for the treatment or prevention of cachexia

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI

Shoulder joint exerciser

ActiveCN117017699Bhigh speedlarge damping forceInjury causeTruncal muscle weakness
This invention discloses a shoulder joint exerciser, including a shoulder brace and an upper arm brace, with a hinged rod assembly between them to maintain deflection. A first rod hinged to the back of the shoulder brace is rotatably connected to the end of a second rod hinged to the back of the upper arm brace. An electric push rod is rotatably mounted on the first rod, with its output end hinged to the second rod and positioned close to the upper arm brace. The device also includes a worm gear, with worm wheels respectively mounted on the shafts connecting the first and second rods to the shoulder brace and upper arm brace, the worm gear meshing with the worm wheels. This shoulder joint exerciser has a simple structure and is easy and quick to operate. It avoids the pain or secondary injury caused by the arm falling rapidly during arm raising and lowering due to muscle weakness or poor coordination.
Owner:ZHUZHOU TRAUMATOLOGY HOSPITAL OF TRADITIONAL CHINESE MEDICINE

Stroke patient NIHSS score automatic evaluation system

The application relates to the technical field of intelligent medical auxiliary diagnosis and automatic evaluation of nerve functions, in particular to an NIHSS score automatic evaluation system for stroke patients. The system comprises a multi-modal induction and perception unit, which is used as a front-end data inlet and collects patient responses in real time to generate a video stream containing depth and color information and a synchronous audio stream; a dynamic reference calibration unit, which extracts kinematic characteristics to construct an individualized neural reference template; a neural motion frequency spectrum decomposition unit, which generates a frequency spectrum pathological characteristic vector distinguishing muscle weakness and ataxia; a contralateral mirror inhibition analysis unit, which generates compensation and driving confidence representing real neural driving intentions; a cross-modal reflection analysis unit, which generates a sensory pathway integrity index according to the difference in nerve conduction velocity; and a collaborative scoring decision engine, which maps multi-modal characteristics to a standardized NIHSS score. The application effectively eliminates the interference of age and basic physical fitness on the score, and can also provide high-precision comparison references for subsequent abnormality determination of the affected side.
Owner:THE FIRST AFFILIATED HOSPITAL OF MEDICAL COLLEGE OF XIAN JIAOTONG UNIV

Activin receptor type II chimeras and methods of use thereof

ActiveUS12522646B2Antibody mimetics/scaffoldsPeptide/protein ingredientsActivin Receptors Type IIDisease
The invention features polypeptides that include an extracellular ActRII chimera. In some embodiments, a polypeptide of the invention includes an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.
Owner:KEROS THERAPEUTICS INC

Compositions for improving male menopausal symptoms such as decreased libido, erectile dysfunction (ED), depression, and muscle weakness, and medicines, foods, and beverages containing the same for preventing and improving male menopausal symptoms

ActiveJP7818243B2FungiNervous disorderSexual impotenceTruncal muscle weakness
To provide a new male climacteric disorder-ameliorating composition using a safe material free from side effects, and to provide a medicine, food and drink containing the composition.SOLUTION: The male climacteric disorder-improving composition contains a treated product of an Agaricus fruit body.SELECTED DRAWING: Figure 13
Owner:TOEI SHINYAKU CO LTD +1

Hanging tool for dumbbell handle of body builder

The utility model provides a hanger for dumbbell handles of fitness equipment, which relates to the technical field of fitness equipment placing racks and comprises an adjusting plate and two groups of hangers symmetrically mounted on two sides of the front of the adjusting plate. The hanger main body is hollow rectangular and is provided with an opening away from the adjusting plate end, an in-out limiting structure is arranged on the inner side of the long edge of the top end of the hanger close to the opening, a bending area is arranged on the long edge of the bottom of the hanger close to the adjusting plate, and a lower guide plate is upwards inclined at the edge away from the adjusting plate end; by means of the designed in-out limiting structure, the designed bending area and the designed lower guide plate, it is guaranteed that the dumbbell handle can only be placed and taken in a stable holding and flat holding mode, the risk that the dumbbell falls off due to improper operation or force disengaging exercise is greatly reduced, and therefore the possibility of personnel injury and article damage is reduced.
Owner:QINGDAO ENPENG METAL PROD CO LTD

Activin receptor type IIB variants and uses thereof

PendingUS20260139032A1Polypeptide with localisation/targeting motifAntibody mimetics/scaffoldsTruncal muscle weaknessCardiometabolic disease
There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).
Owner:35PHARMA INC

Polypeptides and pharmaceutical compositions comprising activin type IIB receptor mutants

PendingJP2026010032AFungiBacteriaDiseaseTruncal muscle weakness
To provide polypeptides and pharmaceutical compositions comprising activin type IIB receptor variants.SOLUTION: The polypeptide of the present invention comprises an extracellular activin type IIB receptor (ActRIIB) mutant comprising an amino acid sequence consisting of a specific sequence, wherein the C-terminus of the ActRIIB mutant is fused to a human IgG1Fc domain monomer. The invention also features pharmaceutical compositions and methods of using the same to treat diseases and conditions involving muscle weakness and atrophy, bone damage, low red blood cell levels (e.g., anemia or blood loss), fibrosis, and / or pulmonary hypertension.SELECTED DRAWING: Figure 2
Owner:KEROS THERAPEUTICS INC

GLP-1 receptor agonist combinations and use thereof for increasing weight loss while improving muscle mass and strength

PCT designated stageWO2026090181A1Organic active ingredientsMetabolism disorderGaining weightMuscle loss
Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient being treated with a GLP-1 receptor agonist, by administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a patient are also provided.
Owner:EMMYON INC

Cannabinoid Based Nanoplatform Composition and Methods for treating knee osteoarthritis

This document presents a novel composition and method for treating osteoarthritis using a cannabinoid-based nanoplatform administered via intra-articular injection. The composition includes phytocannabinoids such as CBG and CBC, along with hyaluronic acid, type II collagen, and calcium gluconate, embedded within a nanoplatform designed to enhance bioavailability and ensure controlled release in the synovial space. Tailored for osteoarthritis patients, the treatment alleviates joint pain, stiffness, reduced mobility, inflammation, sensations of friction, muscle weakness, and joint deformity. Cannabinoids act through multiple mechanisms, including interaction with CB1 and CB2 receptors, cytokine modulation, inhibition of NF-κB, and activation of the TRPV1 receptor, providing a potent anti-inflammatory effect. The formulation aims to halt cartilage degeneration, reduce pain, and slow osteoarthritis progression. The production process uses nanoemulsification techniques to create particles smaller than 200 nm, with pre-sterilization through membrane filtration, ensuring both efficacy and safety.
Owner:CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS INC

A complex preparation for improving muscle wasting syndrome

PendingCN122097440AOrganic active ingredientsMuscular disorderTruncal muscle weaknessNutrition
The application discloses a compound preparation beneficial to muscle nutrition, which is composed of yeast extract powder, yeast beta-1, 3-glucan and ginsenoside at a weight ratio of 8:1:1, and contains 200-800 mg of yeast extract powder in each unit of the preparation; wherein the essential amino acids beneficial to muscle nutrition include three branched-chain amino acids, specifically isoleucine, leucine and valine, and the ratio coefficient of the branched-chain amino acids is 1-1.2, and the ratio coefficient range is 0.94-1.14. The compound preparation can improve the symptoms caused by muscle attenuation syndrome, such as muscle weakness, osteoporosis and myocardial function degradation, has the advantages of easy absorption, high safety, synergistic effect and the like, and is suitable for the old, the weak and the people with decreased sports ability.
Owner:NANTONG QIUZHIYOU NUTRITIONAL FOOD CO LTD +1

GLP-1 receptor agonist and ursolic acid combinations and use thereof for increasing weight loss while improving muscle mass and strength

PCT designated stageWO2026090182A1Metabolism disorderPeptide/protein ingredientsGaining weightTruncal muscle weakness
Disclosed are methods of improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, increasing muscle mass, and / or increasing muscle strength in a subject being treated with a GLP-1 receptor agonist, by administering to the subject a compound of formula (I) or a pharmaceutically acceptable salt thereof. Combinations of a GLP-1 receptor agonist and a compound of formula (I) or a pharmaceutically acceptable salt thereof for use in improving weight loss, reducing body weight, reducing body fat mass, reducing muscle loss, reducing muscle atrophy, reducing muscle weakness, increasing muscle mass, and / or increasing muscle strength in a subject are also provided.
Owner:EMMYON INC

Products and methods for treating diseases or conditions associated with progerin expression from an aberrant LMNA gene

PCT designated stageWO2025240690A2EnzymesAnimals/human peptidesPremature agingExon
Disclosed herein are products, methods, and uses for treating, ameliorating, delaying the progression of, and / or preventing a disease or disorder associated with expression of an aberrant lamin A (LMNA) gene or progerin gene. Such disease or disorder includes, but is not limited to, a laminopathy, progeroid syndrome, progeria, or aging disorder resulting from the aberrant expression of LMNA or progerin. In some instances, the progeria is Hutchinson-Gilford progeria syndrome (HGPS). In some instances, the disease or disorder associated with the expression of progerin is premature aging or natural aging including, but not limited to, atherosclerosis, alopecia, osteoporosis, cardiovascular disease, skin abnormalities, fat storage, stroke, myocardial infarction, stroke, heart failure, muscle wasting, muscle weakness, myotonia, skeletal muscle problems, abnormalities of the retina, hip weakness, abdominal muscle weakness, joint and spinal abnormalities, lower leg weakness, shoulder weakness, hearing loss, and / or tissue inflammation. More particularly, disclosed herein are RNA interference-based products, methods, and uses for inhibiting or downregulating the expression of progerin. Even more particularly, the disclosure provides guide RNA and a CRISPR endonuclease for inhibiting or downregulating the expression of progerin and methods of using said guide RNA and a CRISPR endonuclease to correct a mutation in the LMNA gene and inhibit or downregulate progerin expression in cells and / or in cells of a subject having a condition resulting from the expression of progerin including, but not limited to, HGPS or progeria, an HGPS-like condition affecting LMNA mutations that affect exon 11 splicing, or a condition resulting from the expression of progerin.
Owner:RES INST AT NATIONWIDE CHILDRENS HOSPITAL

System and method for early post-lung transplant assisted standing position to promote lung inflation

PendingCN122272320AMuscle strengthTruncal muscle weakness
This invention discloses an early assisted standing posture system and method to promote lung expansion after lung transplantation, belonging to the field of medical rehabilitation technology. The system includes a data acquisition module, a muscle strength assessment and compensation decision module, a power-assisted execution module, an embracing psychological support module, an emotion monitoring and response module, and a process control module. It uses multi-sensor fusion technology to identify the specific locations of muscle weakness in patients in real time, uses intelligent decision-making algorithms to calculate the required compensation assistance, and provides dynamic compensation through precise power-assisted devices. At the same time, it integrates multi-dimensional psychological support such as a forward embracing structure, voice guidance, and bionic body temperature and tactile feedback to achieve a synergistic effect of physiological function compensation and psychological and emotional support, providing safe, efficient, and humane early standing rehabilitation training for patients after lung surgery.
Owner:THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)

Method for stir-frying ginseng and method for preparing ginseng nourishing paste containing stir-fried ginseng

PendingCN121287768AAerosol deliveryMuscular disorderBiotechnologyTruncal muscle weakness
The invention discloses a stir-frying method of ginseng and a preparation method of ginseng nourishing paste containing the stir-fried ginseng. The ginseng stir-frying method comprises the following steps: performing biological infiltration on ginseng by using active dry yeast under an acidic condition, and then performing high-pressure steaming with specific parameters and low-temperature long-time drying. According to the processing method, the ginsenoside Rg component easily causing'internal heat 'can be remarkably converted and reduced, other rare saponins are enriched, and the'slow tonifying' characteristic of ginseng is achieved. On the basis, the invention also provides a preparation method of the ginseng nourishing paste, and the preparation method comprises the following steps: scientifically matching the stir-fried radix ginseng, radix astragali, rhizoma polygonati, folium cortex eucommiae, rhizoma dioscoreae and other medicinal and edible raw materials, extracting with ethanol, concentrating, and co-refining with erythritol and other auxiliary materials to obtain the paste. According to the nourishing paste, the tonifying effect of the ginseng core is reserved, meanwhile, the taste and bioavailability are greatly improved, and the nourishing paste is suitable for being taken by middle-aged and elderly people especially people with muscular tension weakness caused by degenerative amyotrophy for a long time so as to achieve the health-care effects of tonifying qi, relieving desertion, relaxing the channels, dredging collaterals, activating the pulse and preventing the degenerative amyotrophy and the muscular tension weakness.
Owner:DEMING SHENZHOU BIOENGINEERING (BEIJING) CO LTD +1

A composition containing three strains of Lactobacillus, and its uses.

This invention provides a mixture of three strains of Lactobacillus fermentum and Lactobacillus platarum, as well as its uses. [Solution] A composition comprising a mixture of Lactobacillus fermentum GB102, GB103 strains and Lactobacillus plantarum GB104 strain, and their lysates, cultures, or extracts of cultures as active ingredients, can be usefully used for the prevention or treatment of muscle-related diseases or obesity, such as by alleviating age-related muscle weakness symptoms or reducing age-related changes in the intestinal microbial environment.
Owner:GI LONGEVITY CO LTD

System suitable for detecting cardiac function in walk test, and electronic device thereof

PCT designated stageWO2026067035A1CatheterSensorsTruncal muscle weaknessWalking time
Disclosed are a system for detecting a cardiac function in a walk test, and an electronic device thereof, comprising: acquiring first inertial measurement information, wherein the first inertial measurement information represents inertial measurement information of a subject's body; extracting to obtain, according to the first inertial measurement information, seismocardiogram information; extracting to obtain, according to the first inertial measurement information, walking information; and analyzing to obtain, according to the seismocardiogram information and the walking information, an identification result regarding cardiac function. Without being limited by walking sites, walking time, and medical staff, the use of a walk test outside the hospital is greatly facilitated, the specificity of cardiac function assessment is achieved, and the interference to data processing caused by other diseases, such as muscle weakness and pulmonary dysfunction of a subject during walking, is eliminated.
Owner:SHANGHAI RUIWEI DIGITAL TECHNOLOGY CO LTD

Exercise device for preventing sarcopenia in the elderly

ActiveCN120771518BWeightsMuscular weaknessLower limb exercises
The application discloses a kind of exercise devices for preventing sarcopenia in old age, belong to exercise equipment technical field, a kind of exercise devices for preventing sarcopenia in old age, including pedestal, the top of pedestal is set adjustable armchair, lower limb auxiliary movement component, upper limb auxiliary movement component;Adjustable armchair is used to switch the sitting posture or standing posture of old user, and it includes protective frame, seat back, movable chair pad, chair pad translation control structure, lifting control structure;Lower limb auxiliary movement component is used to cooperate the lower limb movement of old user, and it includes adjusting structure, footrest type trainer;Upper limb auxiliary movement component is used to cooperate the upper limb movement of old user, and it includes high frame, counterweight structure, anti-falling protection structure.It can have two kinds of movement modes, can solve the single drawback of conventional exercise equipment, and when old in movement appears muscle weakness, can effectively prevent the safety accident caused by the falling of sports props, guarantee the safety performance of entire equipment when using.
Owner:FUJIAN HEALTH COLLEGE

Activin receptor type IIB variants and uses thereof

PendingUS20260092096A1Antibody mimetics/scaffoldsMetabolism disorderTruncal muscle weaknessCardiometabolic disease
There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and / or low red blood cell levels (such as anemia).
Owner:GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 3) LIMITED

System suitable for detecting cardiac function in walking test and electronic equipment thereof

PendingCN121445358ACatheterSensorsTruncal muscle weaknessWalking time
The invention provides a system suitable for detecting cardiac functions in a walking test and electronic equipment thereof, and the method comprises the following steps: obtaining first inertial measurement information which represents inertial measurement information of a subject body; according to the first inertial measurement information, extracting heart earthquake information; according to the first inertial measurement information, extracting walking information; and according to the cardiac shock information and the walking information, analyzing to obtain an identification result about the cardiac function. The method is not limited by walking sites, walking time and medical staff, greatly facilitates use of walking tests outside hospitals, achieves specificity of cardiac function evaluation, eliminates interference of muscle weakness, pulmonary dysfunction and other diseases of subjects in the walking process on data processing, and improves the accuracy of cardiac function evaluation. The method is an innovative development of traditional walking tests which are used for many years all over the world.
Owner:SHANGHAI RUIWEI DIGITAL TECHNOLOGY CO LTD

Activin receptor type ii chimeras and methods of use thereof

PendingJP2025179059AFungiBacteriaActivin Receptors Type IIDisease
To provide polypeptides that include an extracellular ActRII chimera.SOLUTION: Provided is a polypeptide of the present invention including an extracellular ActRII chimera fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, bone damage, low red blood cell levels (e.g., anemia or blood loss), low platelet levels (e.g., thrombocytopenia), low neutrophil levels (e.g., neutropenia), fibrosis, metabolic disorders, and / or pulmonary hypertension.SELECTED DRAWING: None
Owner:KEROS THERAPEUTICS INC

An intelligent physiological training parameter optimization and adjustment system and method

PendingCN122460894ATruncal muscle weaknessMedicine
The application discloses a kind of intelligent physiological training parameter optimization adjustment system and method, belong to physiological training control technical field, including: first, obtain user multi-source baseline physiological signal sequence and training stage parameter, identify skeletal muscle fiber type and construct multi-training target decoupling control model, generate the control configuration data containing muscle fiber targeted execution action parameter interval, dynamic safety threshold curve, body pressure-muscle collaborative constraint rule;Subsequently, start parameter iteration optimization, collect physiological feedback signal, calculate four core indexes, and output muscle basic function diagnosis result after comprehensive difference meets standard;Finally, output rehabilitation action according to preset rhythm, continuously collect signal and identify abnormality such as spasm, muscle weakness, trigger intensity rollback or enhancement mechanism;The application realizes the precision, intelligent adjustment of pelvic floor rehabilitation parameter, improves rehabilitation safety and effectiveness, adapts to the individualized rehabilitation needs of different users.
Owner:SHANGHAI WICRESOFT +1

Space capsule nanometer bath therapy instrument

PendingCN121370588AOperating tablesBathing devicesHuman bodyTruncal muscle weakness
The invention relates to a space capsule nanometer bath therapy instrument which comprises a base, and a bath cabin is arranged at the upper end of the base. A closed bath cavity is formed in the bath cabin, a human body lies on the bath cabin, and the part below the head of the human body is located in the bath cavity; a nano particle bath assisting device is arranged in the base, and water is converted into vaporific nano water particles by the nano particle bath assisting device; a spray pipe located in the bath cavity is arranged in the bath cabin, an outlet of the spray pipe faces the human body, and an inlet is connected with an outlet of the nanoparticle bath assisting device; the inner cavity of the base, the nano particle bath assisting device, the spray pipe and the bath cavity form an annular channel; and the nano-particle bath assisting device comprises a centrifugal fan, so that nano-water particles circularly flow in the channel. The lying type design is adopted, the potential safety hazards such as falling and slipping caused by muscle weakness, poor balance capacity or limited joint movement are effectively avoided, the lying type bathing device is particularly suitable for disabled and semi-disabled people and postoperative rehabilitation patients, and the safety risk caused by a traditional showering mode is greatly reduced.
Owner:JIANGSU FOUR GENERATIONS & ELDERLY CARE IND DEVELOPMENT CO LTD +1

Activin receptor type IIA variants and methods of use thereof

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.
Owner:KEROS THERAPEUTICS INC

Activin IIB type receptor variants and uses thereof

PendingCN121729426APolypeptide with localisation/targeting motifAntibody mimetics/scaffoldsTruncal muscle weaknessCardiometabolic disease
The present disclosure provides polypeptides comprising an activin type IIB receptor (ActRIIB) extracellular domain (ECD) variant. In some embodiments, the polypeptides of the present disclosure include an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides in the treatment of diseases and conditions associated with TGF [beta] superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiac metabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone injury, and / or low red blood cell levels, such as anemia.
Owner:35 PHARMACEUTICAL CO LTD